Uberto Pagotto, ESPE 2022: The global health burden and challenges of obesity
Paediatric obesity is a major threat to health and longevity. Around 7% of children worldwide have early onset severe obesity before the age of 7. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy) discusses the global health burden of obesity as well as the challenged obesity comes with.
The abstract entitled: ‘Novel Advances in Obesity‘ was presented at the European Society for Paediatric Endocrinology, 15-17 Sept, 2022.
- Could you give us a brief overview of the global health burden of obesity? (0:18)
- What are the challenges of the treatment of obesity? (2:29)
Disclosures: Uberto Pagotto has received honorarium from Bruno Pharma.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ESPE 2022
Share this Video
Related Videos In Paediatric Endocrinology
Bradley Miller, ESPE 2022: Advantages of somapacitan versus daily GH in children with GH deficiency
Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the challenges of GH therapy in children and the […]
Bradley Miller, ESPE 2022: Once-weekly somapacitan versus daily GH in children with GH deficiency: The REAL 4 trial
The REAL 4 trial is a multicenter, randomized, controlled, double-blind phase 3 study (NCT03811535) to evaluate the efficacy, safety, and tolerability of once-weekly somapacitan vs once-daily growth hormone (GH). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the aims, design and results of the REAL 4 trial. The next […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!